ArticleJournal of cosmetic dermatology2025
KT-939: A Next-Generation Human Tyrosinase Inhibitor With Superior Efficacy for the Safe Management of Hyperpigmentation.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KT-939: A Next-Generation Human Tyrosinase Inhibitor With Superior Efficacy for the Safe Management of Hyperpigmentation.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTyrosinase is the rate-limiting enzyme in melanin biosynthesis, and its overactivity contributes to hyperpigmentation disorders. Existing tyrosinase inhibitors are often limited by poor potency against human tyrosinase (hTYR) or safety concerns.
aimsTo evaluate the inhibitory potency, safety, and multifunctional activity of KT-939, a newly synthesized human tyrosinase inhibitor, compared with established depigmenting agents. PATIENTS/
methodsKT-939 was synthesized and tested in vitro for tyrosinase inhibition, melanin suppression in human melanocytes, antioxidant activity (DPPH radical scavenging, NRF2 pathway activation), and anti-inflammatory activity (cytokine expression in LPS-stimulated macrophages). Safety was assessed in multiple skin-related cell lines. A 28-day, single-center clinical study in healthy women with sensitive skin assessed the effects of 0.2% KT-939 lotion on pigmentation and tolerability.
resultsKT-939 strongly inhibited hTYR (IC₅₀ = 0.07 μM), demonstrating ~4-fold greater potency than Thiamidol and far surpassing other comparators. In melanocytes, KT-939 reduced melanin production (IC₅₀ = 0.36 μM) with reversible effects upon withdrawal. KT-939 also displayed antioxidant activity, NRF2 activation, and suppression of pro-inflammatory cytokines, without cytotoxicity up to 50 μM. Clinically, 28 days of KT-939 lotion use improved skin spot lightening, tone uniformity, and overall brightness, with good tolerability in sensitive skin.
conclusionsKT-939 is a potent and safe human tyrosinase inhibitor with additional antioxidant and anti-inflammatory activity. These findings support its potential in cosmetic skin brightening and as a therapeutic candidate for hyperpigmentation disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.